Sandra Pietrzak1, Janusz Wójcik2, Rodney J Scott3, Aniruddh Kashyap1, Tomasz Grodzki2, Piotr Baszuk1, Michał Bielewicz2, Wojciech Marciniak4, Norbert Wójcik2, Tadeusz Dębniak1, Bartłomiej Masojć5, Jarosław Pieróg2, Cezary Cybulski1, Jacek Gronwald1, Małgorzata Wojtyś2, Bartosz Kubisa2, Grzegorz Sukiennicki1, Jakub Deptuła1, Piotr Waloszczyk6, Anna Jakubowska1, Jan Lubiński7, Marcin R Lener8. 1. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252, Szczecin, Poland. 2. Department of Thoracic Surgery and Transplantation, Pomeranian Medical University, ul. A. Sokołowskiego 11, 70-891, Szczecin, Poland. 3. Medical Genetics, Hunter Medical Research Institute; Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle; Pathology North, John Hunter Hospital, Cnr King and Auckland Streets, Newcastle, NSW, 2300, Australia. 4. Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003, Dobra (Szczecińska), Poland. 5. Radiation Oncology Department, West Pomeranian Oncology Center, ul. Strzałowska 22, 71-730, Szczecin, Poland. 6. Independent Laboratory of Pathology, Zdunomed, ul. Energetyków 2, 70-656, Szczecin, Poland. 7. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252, Szczecin, Poland; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003, Dobra (Szczecińska), Poland. 8. Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, ul. Unii Lubelskiej 1, 71-252, Szczecin, Poland. Electronic address: marcinlener@poczta.onet.pl.
Abstract
BACKGROUND: Although the results of studies in populations with low selenium status indicate an inverse correlation between body selenium levels and the risk of the lung cancer, the effect of this microelement on survival has not been studied. MATERIALS AND METHODS: We performed a prospective study of 302 patients diagnosed with lung cancer in Szczecin, Poland. Selenium concentration in serum was measured at the time of diagnosis and before treatment. All patients were followed for a maximum of 80 months or until death. Vital status was obtained from the Polish National Death Registry. RESULTS: Using Cox proportional hazard analysis, performed for all individuals with lung cancer, the hazard ratio (HR) for death from all causes was 1.25 (95% CI: 0.86-1.83, P = 0.99) for patients in the lowest tertile compared to those in the highest tertile of serum selenium levels. Among the patients with stage I disease this relationship was significant (HR-2.73; P = 0.01) for selenium level in tertile 1 (<57 μg/L) compared to tertile 3 (>69 μg/L, reference). The 80 months crude survival after diagnosis was 79.5% (95% CI: 68.5-92.4%) for individuals in the highest tertile and 58.1% (95% CI: 45.1-74.9%) for individuals in the lowest tertile with stage I lung cancer. CONCLUSION: These results suggest that in patients undergoing treatment for stage I lung cancer, serum selenium levels at the time of diagnosis (>69 μg/L) may be associated with improved overall survival.
BACKGROUND: Although the results of studies in populations with low selenium status indicate an inverse correlation between body selenium levels and the risk of the lung cancer, the effect of this microelement on survival has not been studied. MATERIALS AND METHODS: We performed a prospective study of 302 patients diagnosed with lung cancer in Szczecin, Poland. Selenium concentration in serum was measured at the time of diagnosis and before treatment. All patients were followed for a maximum of 80 months or until death. Vital status was obtained from the Polish National Death Registry. RESULTS: Using Cox proportional hazard analysis, performed for all individuals with lung cancer, the hazard ratio (HR) for death from all causes was 1.25 (95% CI: 0.86-1.83, P = 0.99) for patients in the lowest tertile compared to those in the highest tertile of serum selenium levels. Among the patients with stage I disease this relationship was significant (HR-2.73; P = 0.01) for selenium level in tertile 1 (<57 μg/L) compared to tertile 3 (>69 μg/L, reference). The 80 months crude survival after diagnosis was 79.5% (95% CI: 68.5-92.4%) for individuals in the highest tertile and 58.1% (95% CI: 45.1-74.9%) for individuals in the lowest tertile with stage I lung cancer. CONCLUSION: These results suggest that in patients undergoing treatment for stage I lung cancer, serum selenium levels at the time of diagnosis (>69 μg/L) may be associated with improved overall survival.
Authors: Kamil Demircan; Qian Sun; Ylva Bengtsson; Petra Seemann; Johan Vallon-Christersson; Martin Malmberg; Lao H Saal; Lisa Rydén; Waldemar B Minich; Åke Borg; Jonas Manjer; Lutz Schomburg Journal: Redox Biol Date: 2022-05-25 Impact factor: 10.787
Authors: Sascha Venturelli; Christian Leischner; Thomas Helling; Olga Renner; Markus Burkard; Luigi Marongiu Journal: Cancers (Basel) Date: 2022-02-28 Impact factor: 6.639
Authors: Marek Szwiec; Wojciech Marciniak; Róża Derkacz; Tomasz Huzarski; Jacek Gronwald; Cezary Cybulski; Tadeusz Dębniak; Anna Jakubowska; Marcin Lener; Michał Falco; Józef Kładny; Piotr Baszuk; Jerzy Duszyński; Joanne Kotsopoulos; Steven A Narod; Jan Lubiński Journal: Nutrients Date: 2021-03-16 Impact factor: 5.717